Literature DB >> 19289461

The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Megumi Funakoshi-Tago1, Kenji Tago, Kazuya Sumi, Miyuki Abe, Eriko Aizu-Yokota, Tomoyuki Oshio, Yoshiko Sonoda, Tadashi Kasahara.   

Abstract

JAK2 plays important roles in the regulation of a variety of cellular processes including cell migration, proliferation, and protection from apoptosis. Recently the L611S point mutation in JAK2 has been identified in a child with acute lymphoblastic leukemia. Here we analyzed the mechanism by which JAK2 exhibits its oncogenicity. In BaF3 murine hematopoietic cells, L611S mutant increased the expression of antiapoptotic proteins including X chromosome-linked inhibitor of apoptosis protein, inhibitor of apoptosis protein, and Bcl-XL. We also showed that JAK2 L611S mutant protects BaF3 cells from cytokine withdrawal-induced apoptotic cell death and leads to cytokine-independent cell growth. Furthermore BaF3 cells expressing JAK2 L611S mutant gained the ability to induce tumorigenesis in nude mice. The L611S mutant also exhibited malignancy, including prompt invasion and spreading into various organs, leading to rapid lethality of the mice. Finally we showed that a specific JAK2 inhibitor, AG490, potently inhibited cytokine-independent cell growth induced by JAK2 L611S mutant via the induction of apoptotic cell death. In addition, treatment with AG490 significantly inhibited the JAK2 L611S mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo strongly suggest that L611S mutant of JAK2 harbors potent oncogenic activity, and this probably requires the antiapoptotic signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289461      PMCID: PMC2675997          DOI: 10.1074/jbc.M808879200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia.

Authors:  C P Kratz; S Böll; U Kontny; M Schrappe; C M Niemeyer; M Stanulla
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

Review 2.  Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

Authors:  Lynda A O'Sullivan; Clifford Liongue; Rowena S Lewis; Sarah E M Stephenson; Alister C Ward
Journal:  Mol Immunol       Date:  2007-01-17       Impact factor: 4.407

Review 3.  Hematopoietic cytokine receptor signaling.

Authors:  S J Baker; S G Rane; E P Reddy
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

Review 4.  JAK-STAT signaling: from interferons to cytokines.

Authors:  Christian Schindler; David E Levy; Thomas Decker
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

5.  Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Chiho Nishizawa; Kyoko Takahashi; Tadahiko Mashino; Susumu Iwata; Hideo Inoue; Yoshiko Sonoda; Tadashi Kasahara
Journal:  Biochem Pharmacol       Date:  2008-09-19       Impact factor: 5.858

6.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

7.  The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes.

Authors:  A Khoshnan; C Tindell; I Laux; D Bae; B Bennett; A E Nel
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

8.  Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.

Authors:  Megumi Funakoshi-Tago; Stéphane Pelletier; Hiroshi Moritake; Evan Parganas; James N Ihle
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

Review 9.  Cotargeting survival signaling pathways in cancer.

Authors:  Steven Grant
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Authors:  Carolyn Waugh Kinkade; Mireia Castillo-Martin; Anna Puzio-Kuter; Jun Yan; Thomas H Foster; Hui Gao; Yvonne Sun; Xuesong Ouyang; William L Gerald; Carlos Cordon-Cardo; Cory Abate-Shen
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more
  10 in total

1.  Germline JAK2 L611S mutation in a child with thrombocytosis.

Authors:  Bernard Aral; Martine Courtois; Sylviane Ragot; Valentin Bourgeois; Elodie Bottolier-Lemallaz; Claire Briandet; François Girodon
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

2.  STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Miyuki Abe; Yoshiko Sonoda; Tadashi Kasahara
Journal:  J Biol Chem       Date:  2009-12-22       Impact factor: 5.157

3.  ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway.

Authors:  Tatiana Vignudelli; Tommaso Selmi; Andrea Martello; Sandra Parenti; Alexis Grande; Claudia Gemelli; Tommaso Zanocco-Marani; Sergio Ferrari
Journal:  Mol Biol Cell       Date:  2010-08-11       Impact factor: 4.138

Review 4.  Janus kinase deregulation in leukemia and lymphoma.

Authors:  Edwin Chen; Louis M Staudt; Anthony R Green
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

Review 5.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

6.  Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.

Authors:  Qian Li; Botao Li; Liangding Hu; Hongmei Ning; Min Jiang; Danhong Wang; Tingting Liu; Bin Zhang; Hu Chen
Journal:  Oncotarget       Date:  2017-05-23

7.  A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis.

Authors:  Sherine J Thomas; D P Dash
Journal:  Case Rep Hematol       Date:  2022-02-21

Review 8.  JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Authors:  Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White
Journal:  Front Cell Dev Biol       Date:  2022-07-12

9.  Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.

Authors:  Megumi Funakoshi-Tago; Kazuya Sumi; Tadashi Kasahara; Kenji Tago
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

10.  EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.

Authors:  Yuki Uchihara; Kenji Tago; Hiroomi Tamura; Megumi Funakoshi-Tago
Journal:  Mol Oncol       Date:  2020-11-19       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.